Mira Pharmaceuticals (MIRA) Common Equity (2022 - 2025)
Mira Pharmaceuticals (MIRA) posted Common Equity of $10.4 million for Q4 2025, up 37.65% sequentially from $7.5 million in Q3 2025, and up 372.34% YoY from $2.2 million in Q4 2024.
Mira Pharmaceuticals (MIRA) Common Equity (2022 - 2025) Analysis & Trends
Mira Pharmaceuticals has reported Common Equity for 4 years, with the latest figure at $10.4 million in Q4 2025.
- Quarterly Common Equity rose 372.34% year-over-year to $10.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.4 million (up 372.34% YoY) and the FY2025 annual result came in at $10.4 million, up 372.34% from the prior year.
- Common Equity improved to $10.4 million in Q4 2025 per MIRA's latest filing, from $7.5 million in the prior quarter.
- Over five years, Common Equity peaked at $10.4 million in Q4 2025 and troughed at -$1.8 million in Q1 2023.
- A 4-year average of $3.0 million and a median of $2.2 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2025: Common Equity jumped 2432.48% in 2023, then tumbled 74.32% in 2025.
- Over 4 years, Common Equity stood at -$596232.0 in 2022, then surged by 833.67% to $4.4 million in 2023, then plunged by 49.71% to $2.2 million in 2024, then surged by 372.34% to $10.4 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $10.4 million, $7.5 million, and $569859.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Mira Pharmaceuticals | 18.47 Mn | 7.44 Mn | - | 10.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.39 Mn |
| Sep 30, 2025 | 7.55 Mn |
| Jun 30, 2025 | 569,859.00 |
| Mar 31, 2025 | 1.29 Mn |
| Dec 31, 2024 | 2.20 Mn |
| Sep 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 2.22 Mn |
| Mar 31, 2024 | 3.16 Mn |
| Dec 31, 2023 | 4.37 Mn |
| Sep 30, 2023 | 8.12 Mn |
| Jun 30, 2023 | 1.20 Mn |
| Mar 31, 2023 | -1.79 Mn |
| Dec 31, 2022 | -596,232.00 |
| Sep 30, 2022 | 320,449.00 |